Wave Life Sciences
WVE
Market cap $1.28B

8.41 USD

-0.09

1.06%

At close Oct 4, 4:00 PM EDT

After hours

8.25

-0.16

1.9%

1 day

-1.06%

5 days

0.96%

1 month

63.94%

3 months

53.75%

6 months

45.00%

Year to date

57.49%

1 year

48.85%

5 years

-55.83%

About: WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Employees: 268

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

57% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 23

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

10% more funds holding

Funds holding: 130 [Q1] → 143 (+13) [Q2]

1.0% more ownership

Funds ownership: 75.53% [Q1] → 76.53% (+1.0%) [Q2]

4% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 45

18% less capital invested

Capital invested by funds: $570M [Q1] → $470M (-$100M) [Q2]

49% less call options, than puts

Call options by funds: $165K | Put options by funds: $325K

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

17%

downside

Avg. target

$13.75

63%

upside

High target

$22

162%

upside

8 analyst ratings

7 positive

88%

1 neutral

13%

0 negative

0%

RBC Capital Luca Issi 24% 1-year accuracy 12 / 51 met price target	17%downside $7	Sector Perform Maintained	4 Oct 2024
B. Riley Securities Madison El-Saadi 0 / 0 met price target	126%upside $19	Buy Maintained	3 Oct 2024
JP Morgan Eric Joseph 44% 1-year accuracy 12 / 27 met price target	55%upside $13	Overweight Reinstated	27 Sept 2024
Jones Trading Catherine Novack 38% 1-year accuracy 3 / 8 met price target	90%upside $16	Buy Maintained	25 Sept 2024
HC Wainwright & Co. Andrew Fein 43% 1-year accuracy 74 / 171 met price target	162%upside $22	Buy Maintained	25 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about WVE published over the past 30 days

24/7 Wall Street

An Airline, Biotechs, and More See Huge Insider Buying

24/7 Wall St. Insights Public offerings of stock and activist investor activity have prompted some huge insider buying.

An Airline, Biotechs, and More See Huge Insider Buying

The Motley Fool

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics

These two could become direct competitors relatively soon.

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it closed its previously announced underwritten public offering, and that the underwriters exercised in full their option to purchase an additional 3,750,000 of its ordinary shares at the public offering price of $8.00 per ordinary share, less underwriting discounts and commissions. After giving effect to the full exercise of the underwriters' option to purchase additional shares, the total number of ordinary shares sold in the offering is 26,875,001 ordinary shares which, along with the sale of pre-funded warrants to purchase 1,875,023 ordinary shares, resulted in aggregate gross proceeds to Wave Life Sciences of approximately $230 million, before deducting underwriting discounts and commissions and offering expenses.

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan 8th Annual Genetic Medicines Conference in New York City on Tuesday, October 1, 2024, at 1:00 p.m. ET.

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences WVE, whose shares rose 9% the day after the central bank reduced rates by 50 basis points.

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875,023 ordinary shares at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Zacks Investment Research

WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study

Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.

WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences.

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Wave Life Sciences' stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.

Wave Life Sciences' stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy patients who display milder disease

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

See News Rankings

Charts implemented using Lightweight Charts™